RiverVest Venture Partners
Venture capitalSt. Louis · Pre-Seed–Late Stage · 22 people tracked
Also known as RiverVest Venture · RIVERVEST VENTURE MANAGEMENT LLC
Find your way into RiverVest Venture Partners
1,806 people in our graph share verified history with the RiverVest Venture Partners team — schools, employers, funds. One of them is your warm intro.
Investment thesis
RiverVest focuses on building life sciences companies, aiming to improve patient outcomes by backing innovation in biotechnology, pharmaceuticals, and medical technology. The firm supports entrepreneurs through a combination of scientific insight, strategic guidance, and operational involvement, and seeks to earn the trust of its investors. Its portfolio spans therapeutics areas such as neurodegenerative disease, rare liver diseases, and metabolic conditions like difficult-to-control type 2 diabetes, reflecting a deep-science approach to venture creation.
Source: firm website, verified Sep 15, 2026.
Team · 22 people
from the firm's website & public directories
What they invest in
from 49 of 76 portfolio companiesBiotech ×37Healthtech ×27Medical Devices ×20Digital Health ×7Enterprise Software ×3AI & Machine Learning ×2Deep Tech ×2Hardware ×2
HQs:United States×38Germany×1Mexico×1Vietnam×1
Who they back
founder profiles across 15 portfolio companiesFounding team size:solo founder×132 founders×2
Investments · 76 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 52024 · 22023 · 32022 · 12021 · 42020 · 32019 · 12018 · 22017 · 22016 · 32015 · 237 dated
Spruce Biosciences develops and commercializes therapies for serious neurological and endocrine disorders with unmet medical need, with a lead investigational enzyme replacement therapy (TA-ERT) for Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B).
BiotechHealthtechSouth San Francisco, US
Javier Szwarcberg(Executive Officer, Director)inSamir Gharib(Executive Officer)inRICHARD KING(Executive Officer, Director)inJavier Szwarcberg, M.D., M.P.H.(Chief Executive Officer)in
BoardSimpson Camilla(Director)Tiba Aynechi(Director)in
Board seatNiall O'Donnell· per SEC Form D
Co-investorsAisling CapitalHealthCapAbingworthNorwest Venture PartnersNovo HoldingsOmega Funds+1 more
Avalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies.
BiotechHealthtech
Lyn Baranowski(CEO)in
Co-investorsAndera PartnersCatalio Capital Management, LPF-Prime CapitalInVivium CapitalNorwest Venture PartnersSR One Capital Management+9 more
MacroGenics is a clinical-stage biopharmaceutical company developing antibody-based therapies for cancer patients.
BiotechHealthtechMedical Devices
Scott Koenig(Director)inEric Risser(President and Chief Executive Officer)in
Co-investorsHavencrest Capital ManagementRidgeback CapitalSanofi VenturesLa CaisseTPG
Mirum Pharmaceuticals is a biopharmaceutical company that develops and delivers therapies for people living with rare diseases.
BiotechHealthtechSan Diego, US
Chris Peetz(Co-founder & Chief Executive Officer)inEric Bjerkholt(Executive Officer)inPeter Radovich(Executive Officer)in
BoardPatrick Heron(Director)inMichael Grey(Director)Timothy Walbert(Director)
Co-investorsChiesi VenturesFrazier Life SciencesNew Enterprise Associates (NEA)Pappas CapitalFrazier Healthcare PartnersNorwest Venture Partners+1 more
OnKure Therapeutics is a clinical-stage biopharmaceutical company developing PI3Kα pan-mutant selective inhibitor medicines for the treatment of breast cancer and vascular anomalies.
BiotechDigital HealthHealthtechMedical DevicesBoulder, US
Jason Leverone(Executive Officer)inSamuel Agresta(Executive Officer)inDylan Hartley(Executive Officer)inWendy Johnson(Executive Officer)Nicholas A. Saccomano(President and Chief Executive Officer and Director)
BoardIsaac Manke(Director)in
Co-investorsAccess BiotechnologyBoulder VenturesAbingworthACORN BIOVENTURESNew Enterprise Associates (NEA)Novo Holdings
Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment.
BiotechHealthtechWaltham, US
René Russo(Executive Officer, Director)inJoseph Farmer(Executive Officer)Timothy Clackson(Executive Officer)Christopher Frankenfield(Chief Financial and Operating Officer)inKatarina Luptakova(Chief Medical Officer)inPaul Clancy(Director)
Co-investorsBain Capital Life SciencesBay City CapitalF-Prime CapitalM VenturesMRL Ventures FundRA Capital+9 more
Engrail Therapeutics is a clinical-stage pharmaceutical company developing precision-targeted therapeutics for neupropsychiatric and neurodevelopmental disorders.
BiotechDigital HealthMedical DevicesSan Diego, US
Stephen(Co-founder, EVP Research & Development and Chief Development Officer)Paul Cayer(Chief Financial Officer)inVikram(President and Chief Executive Officer)Kimberly(Chief Scientific Officer)Quentin(Chief Technical Officer)
Co-investorsForesite CapitalLongwood FundNorwest Venture PartnersYsios Capitalabrdn plcEight Roads Ventures+4 more
Alleviant Medical develops an investigational minimally invasive medical device using interatrial shunt therapy to treat heart failure patients, currently in FDA-approved clinical trials (ALLAY-HF and ALLAY-HFrEF).
BiotechHealthtechMedical DevicesAustin, US
Adam Berman(Executive Officer, Director)inJacob Kriegel(Executive Officer, Director)Avni Patel(Executive Officer, Director)Christopher Alex Arevalos(Executive Officer, Director)Albertien Greijdanus(Executive Officer, Director)
BoardGeoff Pardo(Director)in
Board seatJay W. Schmelter· per SEC Form D
Co-investorsBroadview VenturesTMC Venture FundCadence Healthcare VenturesGilde HealthcareGilmartin Capital LLCS3 Ventures+1 more
Bonum Therapeutics develops antibody-controlled protein therapeutics that remain inactive until bound to their target, using a sensor-domain mechanism to deliver regulated, targeted activity.
BiotechHealthtechSeattle, US
John Mulligan(Executive Officer, Director, Promoter)inNeela Patel(Executive Officer)inDiane Hollenbaugh(Executive Officer)in
BoardSamuel Bjork(Director)inMonique Schiersing(Director)in
Board seatJohn McKearn· per SEC Form D
Co-investorsRoche Venture FundVivo Capital3x5 PartnersCodon CapitalDigitalis Ventures
HealthtechSt. Louis, US
M. Brent Shelton(Executive Officer)Paula Skjefte(Executive Officer, Director)Nick Lanners(Executive Officer)Igor Efimov(Director)
BoardEric A. Gulve(Executive Officer, Director)Warren Watson(Director)
Board seatJay W. Schmelter· per SEC Form D
Co-investorsCultivation Capital
Avalyn Pharma (formerly Genoa Pharmaceuticals) is a biopharma company developing inhaled therapies for idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases.
BiotechHealthtechSan Diego, US
Mark W. Surber, Ph.D.(Executive Officer, Director)Richard G. Vincent(Executive Officer)
BoardMichael J. Kamdar(Director)Daniel D. Burgess(Director)
Board seatNiall O'Donnell· per SEC Form D
Co-investorsF-Prime CapitalNorwest Venture PartnersSofinnova Ventures
InterVene, Inc. is a medical device company that has developed a fully integrated mechanical thrombectomy system to treat venous in-stent restenosis and residual thrombotic venous obstructions and occlusions.
BiotechHealthtechMedical DevicesMountain View, US
Fletcher Wilson(Executive Officer, Director)in
BoardThomas Fogarty(Director)Mel Schatz(Director)
Board seatJay W. Schmelter· per SEC Form D
Co-investorsLaunchCapitalTreo Ventures, LlcEmergent Medical Partners, LLP
Clinical-stage immuno-oncology company developing antibodies derived from the immune systems of 'Elite' cancer responders.
BiotechHouston, US
Alice Bexon(Executive Officer)inClifford J. Stocks(Director, Executive Officer)inKamal D. Puri(Executive Officer)inChris Russell(Executive Officer)inRuss Hawkinson(Executive Officer)
BoardSteven Gillis(Director)in
Board seatJohn McKearn· per SEC Form D
Co-investors3B Future Health FundCanaan PartnersGreatPoint VenturesARCH Venture PartnersBering CapitalIntervest+3 more
EnergyOakland, US
James C David(Executive Officer, Director)Woody Gibson(Executive Officer)Stewart Ramsay(Executive Officer, Director)
BoardAnthony Arnerich(Director)Jay Schmelter(Director)inFrederick Buckman(Director)
Board seatJay W. Schmelter· per SEC Form D · $85.8M raise · filed Jan 2020
Co-investorsEnergy Transition Ventures3x5 Partners
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for cardiometabolic disease.
BiotechHealthtechMedical DevicesPortland, US
Robert Jacks(Executive Officer, Director)inDavid Aaron Katz(Executive Officer, Director)
BoardJonathan Root(Director)inZach Scheiner(Director)inKlaus Veitinger(Director)in
Board seatNiall O'Donnell· per SEC Form D
Co-investorsOrbiMedRA CapitalUS Venture Partners
Allotera (formerly Wugen) develops allogeneic T-cell therapies.
BiotechHealthtechMedical DevicesSt. Louis, US
Ayman Kabakibi(Executive Officer)inCherry Thomas(Executive Officer)inKumar Srinivasan(Executive Officer, Director)inKeith Vendola(Executive Officer)Daniel M Kemp(Executive Officer, Director)Matthew Cooper(Executive Officer)
Board seatNiall O'DonnellJohn McKearn· per SEC Form D
Co-investorsAisling CapitalAlpha Wave GlobalBioGenerator VenturesAbingworthFidelity InvestmentsIntermediate Capital Group+1 more
Portfolio company that completed a successful 2018 biotech IPO, resulting in a 9x return for RiverVest.
BiotechSan Carlos, US
Nenad Tomasevic(Executive Officer)Christopher Bebbington(Executive Officer, Director)Alejandro Dorenbaum(Executive Officer)
BoardFarah Champsi(Director)inJohn McKearn(Director)inPeter Moldt(Director)
Co-investorsAlta PartnersNew Enterprise Associates (NEA)Samsara BioCapitalRoche Venture Fund
St. Louis, US
Co-investorsAisling CapitalLYZZ CapitalAbingworth
Pfizer discovers, develops, manufactures, and distributes pharmaceutical medicines and vaccines across therapeutic areas including oncology, cardiology, immunology, and infectious diseases.
BiotechHealthtechMedical DevicesNew York, US
Charles Pfizer
Co-investorsAisling CapitalAndera PartnersRho Capital PartnersRho VenturesVenrockNew Enterprise Associates (NEA)
AnTolRx develops immunotherapy therapeutics based on research in immune tolerance, targeting immune-mediated disorders.
BiotechHealthtechBoston, US
Francisco J. Quintana(Scientific Founder, Member of Board of Directors)Mark Carthy(Founder and CEO, Member of Board of Directors)
BoardSatish Jindal(Director)
Co-investorsAvego BioScience CapitalBioGenerator VenturesPerot JainRoche Venture FundSR One Capital Management
Atalanta is developing treatment options for intractable central nervous system diseases using RNA interference technology.
BiotechDeep TechHealthtechMedical Devices
Co-investorsF-Prime CapitalNovartis Venture FundSanofi Venturesabrdn plcEQT Life Sciences
Biogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology.
BiotechMedical Devices
Co-investorsAlpha Wave GlobalAsset Management Company
Biolinq develops the Shine sensor, a needle-free glucose monitor that measures glucose along with physical activity and sleep in a single wearable device.
Digital HealthHardwareMedical Devices
Jared Tangney(Founder)inRich Yangin
Co-investorsAble PartnersAlpha Wave GlobalAphelion CapitalAverin CapitalBOLD LongevityFeatures Capital Holdings+3 more
Biolinq develops a non-invasive glucose sensor that uses light to display glucose levels in real time, while also tracking activity and sleep to provide personalized health insights via a mobile app.
BiotechDigital HealthHealthtechMedical DevicesSan Diego, US
Jared Tangney(Executive Officer, Director, Promoter)inRichard Yang(Executive Officer, Director)Edward Kliphuis(Director)
BoardDaniel Bradbury(Director)inLana Ghanem(Director)
Co-investorsAlpha Wave GlobalBeyond CapitalBioBritJDRF T1D FundAphelion CapitalHikma Ventures+1 more
Bluejay develops tools for improving the reliability of generative AI systems in production environments.
AI & Machine LearningDeveloper ToolsEnterprise SoftwareSan Francisco, US
Rohan Vasishth(Founder)inFaraz Siddiqi(Founder)in
Co-investorsFloodgateHomebrewMoonlanding VenturesY CombinatorZAKA VC
Healthcare company acquired by Mirum Pharmaceuticals, a former RiverVest portfolio company.
San Mateo, US
Keting Chu(Executive Officer, Director)inDajun Yang(Director)Nancy Hong(Director)inAlon Lazarus(Director)William J. Rutter(Director)Ting Jia(Director)
Co-investorsFrazier Life SciencesRA CapitalFrazier Healthcare PartnersHBM Healthcare InvestmentsNovo HoldingsT. Rowe Price+1 more
Lifepoint is a diversified healthcare delivery network operating community hospitals, rehabilitation and behavioral health hospitals, and additional sites of care across the healthcare continuum.
Digital HealthHealthtech
Scott Mercy(Founding Chairman and CEO)
Co-investorsRC Capital
Gilead discovers, develops, and delivers innovative therapeutics for people with life-threatening diseases, focusing on virology, oncology, and inflammation across more than 35 countries.
BiotechDigital HealthHealthtechMedical DevicesFoster City, US
Lou Lange(Founder)Michael L. Riordan(Founder)inDaniel O'Dayin
Co-investorsAisling CapitalAsset Management CompanyFrazier Life SciencesKleiner PerkinsLongitude CapitalLumira Ventures+5 more
Captisol is a pharmaceutical-grade sulfobutylether beta-cyclodextrin (SBECD), a derivatized beta cyclodextrin used to solubilize and stabilize difficult-to-deliver molecules across routes such as parenteral, oral, ophthalmic, nasal, and inhalation.
BiotechHealthtechNew Materials
Medtronic designs and develops medical technology for treating complex diseases.
AI & Machine LearningDigital HealthHealthtechMedical Devices
Co-investors8VCCWRU Technology VenturesElevate VenturesMenlo VenturesOak Investment PartnersPfizer Venture Investments+5 more
Bristol Myers Squibb is a biopharmaceutical company that develops and delivers medicines across oncology, hematology, neuroscience, immunology, and cardiovascular disease areas.
BiotechHealthtechMedical DevicesNew York, US
Co-investorsKleiner PerkinsNew Enterprise Associates (NEA)Nextech InvestProspect Venture PartnersRho Capital PartnersRho Ventures+2 more
Glycomine develops therapeutics for rare diseases, many of which currently lack disease-modifying treatment options.
Biotech
Steven Axon(Chief Executive Officer)inHicham Alaoui(Chief Scientific Officer)inRose Marino(Chief Medical Officer)inPeter McWilliams(Chief Business Officer)Geoffrey Hird(Chief Technology Officer)in
Co-investorsAdvent Life SciencesMission Bay CapitalMission BiocapitalRemiges Ventures, Inc.Sanderling VenturesSanofi Ventures
Portfolio company acquired by Roche.
BiotechSeattle, US
John Mulligan(Executive Officer, Director, Promoter)inMitchell Mutz(Director)Nicholas Walrod(Director)
BoardJohn McKearn(Director)inKarl Handelsman(Director)
Co-investorsDigitalis VenturesRoche Venture Fund
Acquired by Shire in 2014 (now part of Takeda).
BiotechMedical Devices
Co-investorsFrazier Life SciencesLongitude CapitalOberland Capital
Maxwell Biomedical develops a device-based alternative to catheter ablation for atrial fibrillation, using closed-loop adaptive left atrial multisite pacing and Spatial Resynchronization Therapy (SRT) to terminate AF without high-energy shock.
BiotechHardwareHealthtechMedical Devices
Randy Werneth(CEO, President)inTimothy Corvi(Sr. VP, R&D)inDerrick Chou(VP, Science & Technology)
Co-investorsBroadview Ventures
Neuros Medical develops the Altius Direct Electrical Nerve Stimulation System, an FDA-approved implantable device that delivers patient-controlled electrical stimulation to treat chronic post-amputation pain in adult lower limb amputees.
BiotechHealthtechMedical DevicesAliso Viejo, US
David Veino(President and CEO)Zach Stassen(Chief Financial Officer)Robert J. Centa(Chief Financial Officer)Jon J. Snyder(Director, President, Secretary and CEO)in
BoardJoyce Erony(Director)inWilliam Harrington(Director)
Co-investorsAmzak HealthAPERTURE Venture PartnersCWRU Technology VenturesiSelect FundJobsOhio VenturesJumpstart Ventures+6 more
Reneo is an asset and investment management platform for decarbonizing residential real estate portfolios in Germany.
Climate TechEnterprise SoftwarePropTechGermany, DE
Lennart Börner(Founder & Co-CEO)inAlexander Graubner-Müller(Founder & Co-CEO)in
Co-investorsFoundamentalAbingworthAisling CapitalAmzak HealthEurazeoLakestar+4 more
Xoilac TV is a free online football (soccer) live-streaming platform serving fans in Vietnam, offering Full HD match broadcasts of European, Asian, Vietnamese, and international competitions.
ConsumerMedia & EntertainmentSports Tech
Co-investorsAisling CapitalNew Enterprise Associates (NEA)Pappas CapitalAbingworthAmzak HealthLundbeckfonden Ventures+2 more
Scout Bio developed biotechnology therapies for pets, including a pipeline of monoclonal antibodies and gene therapy programs targeting chronic diseases in companion animals.
AgTechBiotechDeep TechHealthtechPhiladelphia, US
Mark Hefferman(Executive Officer, Director)
BoardAditya Kohli(Director)inTadataka Yamada(Director)Patrick Heron(Director)inCindy Cole(Director)inNancy Hong(Director)
Co-investorsCompanion FundCorrelation VenturesDigitalis VenturesFrazier Life Sciences
BiotechWaltham, US
Ellen E. Sheets(Executive Officer, Director)in
BoardCarl M. Berke(Director)inNancy Hong(Director)in
Co-investorsBold Capital PartnersDigitalis VenturesKdT Ventures
ShareFile provides secure file sharing, document collection, e-signature capabilities, and automated workflow management for teams collaborating with clients, partners, and vendors.
Enterprise SoftwareSaaS
Co-investorsAstellaBlack Diamond VenturesBrightstone Venture CapitalCID CapitalConcord Health PartnersH Venture Partners+1 more
Standard Bariatrics develops the Titan SGS™ Stapler, a specialized surgical device designed for sleeve gastrectomy procedures that creates consistent and symmetrical gastric pouches using an anatomy-based approach.
Medical Devices
Co-investorsCincyTechEmergent Medical Partners, LLPHatteras Venture PartnersJobsOhio VenturesRC CapitalUS Venture Partners
Statcounter provides website analytics and visitor tracking software that displays traffic data, user behavior, and engagement metrics in a simple interface.
AdTechData & InfrastructureMarketing TechSaaS
Aodhán Cullen(Founder and CEO)
Co-investorsGabriel Venture PartnersHomegrown CapitalHuangpu River CapitalIaso VenturesKumpulan Modal PerdanaNucleation Capital+2 more
BiotechCoppell, US
Alvaro F. Guillem(Executive Officer, Director)Todd Creech(Executive Officer)Donald Jeffrey Keyser(Executive Officer, Director)Cynthia Smith(Executive Officer)Henrick Sandvad Rasmussen(Executive Officer)Robert Alexander(Executive Officer, Director)
Co-investorsSofinnova Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Curzion Pharmaceuticals IncLyric PharmaceuticalsTryton MedicalVasculoxVentureMed Group555 Bryant StreetAmplyx PharmaceuticalsApnex MedicalArchmont Biopharma IncBridgePoint MedicalCabrellisCameron Health IncCodeable TherapeuticsExcaliard Pharmaceuticals IncGlycomineIdev Technologies IncInterVene MedicalLutonixMpex Pharmaceuticals IncMyonid TherapeuticsOtonomyOutriggerOxalurx IncProspex MedicalSalient SurgicalSecurusSecurus Medical Group IncUhcVelocimed LlcZiarco
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 24
6 IPOs · 18 acquisitions · showing 20Spruce BiosciencesNASDAQ: SPRBAvalyn Pharma IncNASDAQ: AVLNMacrogenics IncNASDAQ: MGNXMirum PharmaceuticalsNASDAQ: MIRMOnkure Therapeutics IncNASDAQ: OKURXilio TherapeuticsNASDAQ: XLOCurzion Pharmaceuticals Incacq. by Horizon TherapeuticsBluejay Therapeuticsacq. by Mirum PharmaceuticalsCabrellisacq. by PharmionCameron Health Incacq. by Boston ScientificEpix Therapeuticsacq. by MedtronicExcaliard Pharmaceuticals Incacq. by PfizerGood Therapeuticsacq. by RocheIdev Technologies Incacq. by AbbottLumena Pharmaceuticalsacq. by ShireLutonixacq. by C.R. Bard, Inc.Salient Surgicalacq. by MedtronicScout Bio Incacq. by Ceva Santé AnimaleSecurus Medical Group Incacq. by Boston ScientificVelocimed Llcacq. by St. Jude Medical
Portfolio news
latest coverage across their companiesXilio Therapeutics · tickerreport.com · Aug 15, 2026
Spruce Biosciences · stocktitan.net · Aug 14, 2026
Mirum Pharmaceuticals · finance.yahoo.com · Aug 13, 2026
Smart Wires · datacenterdynamics.com · Jul 27, 2026
Wugen · bizjournals.com · Jul 10, 2026
Bluejay · investing.com · Jun 2, 2026
Avalyn Pharma Inc · investing.com · May 1, 2026
Anacor · sif.gatesfoundation.org · Feb 3, 2026
IPO stake values · per SEC filings · 4
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Mirum Pharmaceuticals | 7.6% | $20.00 | Jan 2020 | $38.4M |
| Onkure Therapeutics Inc | 9.1% | $15.00 | Apr 2021 | $33.1M |
| Spruce Biosciences | 8.5% | $15.00 | Oct 2020 | $28.5M |
| Xilio Therapeutics | 4.5% | $16.00 | Oct 2021 | $19.1M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has RiverVest Venture Partners made?
- RiverVest Venture Partners has 76 tracked investments, 24 of which have exited, including 6 dated in the last 24 months.
- What stage does RiverVest Venture Partners invest at?
- RiverVest Venture Partners invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What is RiverVest Venture Partners's typical check size?
- RiverVest Venture Partners typically writes checks of $500K – $3M.
- What sectors does RiverVest Venture Partners focus on?
- RiverVest Venture Partners focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is RiverVest Venture Partners located?
- RiverVest Venture Partners is headquartered in St. Louis, US.
- Does RiverVest Venture Partners lead rounds?
- Yes, RiverVest Venture Partners leads investment rounds.
- Who does RiverVest Venture Partners co-invest with?
- RiverVest Venture Partners most often shares deals with New Enterprise Associates (NEA), Aisling Capital, Frazier Life Sciences, among 111 tracked co-investors.
Media · Podcasts & interviews
featuring the teamTom Melzer, Managing Director & Co-Founder, RiverVest Venture Partners
InvestMidwest Venture Capital (Forum) · Tom Melzer
Co-investors · 21
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
Abingworth is a life science venture capital firm that backs early-stage biopharma and biotech companies, helping entrepreneurs translate scientific discoveries into new therapeutics.
F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.
Roche Venture Fund is a corporate venture arm that invests in early-stage biotech and diagnostics companies across more than 10 countries, with a portfolio exceeding 30 portfolio companies. The fund is headquartered in Basel, Switzerland.
Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies focused on improving human health. It serves as Sanofi's entry point into the innovation ecosystem.
Digitalis Ventures invests in solutions to unmet needs in biomedicine and health, backing biotechnology and technology-enabled companies across human health and animal health.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
OUP (Osage University Partners) is a venture firm that invests in science-driven startups commercializing deep technology innovations emerging from university and breakthrough research.
SR One is a biotechnology-focused venture capital firm that partners with founders to develop innovative science into new medicines.
S3 Ventures is a venture capital firm founded in 2005 that invests in technology companies and medical device/health software startups, backed by a single philanthropic limited partner.
Pivotal Life Sciences is an investment platform focused on funding innovative companies developing therapeutic products and technologies aimed at major unmet medical needs.
Frazier Healthcare Partners is a healthcare-focused private equity firm that partners with profitable, growing healthcare companies to drive scale and long-term value, pairing high-conviction investment themes with experienced executives.
▶9 more co-investors
Advent Life SciencesCanaan PartnersPolaris PartnersForbionDeerfield Management CompanyDomain AssociatesAlta PartnersCodon CapitalUnknown Ventures
Firms observed investing alongside RiverVest Venture Partners, from public investor directories. Shared companies are the overlap with RiverVest Venture Partners's recorded portfolio.
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
Ambix is a healthcare-focused investment firm that provides funding, strategy, and hands-on support to companies developing medical tools and devices, biochemistry-based technologies, digital health applications, and other novel healthcare solutions. It invests across all stages and also builds companies itself.
SV Health Investors is a healthcare-focused investment firm that invests across multiple stages, geographies and healthcare sectors.
Accelmed Partners is a healthcare technology investment firm that applies a private equity approach to a sector traditionally served by venture and early-stage growth investors, focusing on tools & diagnostics, digital health, and tech-enabled services.